Modulari-T
Modulari-T designs synthetic genes that let engineered immune cells sense their surroundings and change behaviour, so cell therapies can find and kill cancer more reliably.
Overview
Modulari-T, based in Montreal with a San Francisco presence, has designed a family of synthetic genetic modules that reprogramme cells to sense environmental cues and respond, applied first to engineering T cells and other immune cells that recognise and kill tumour cells more efficiently, with a stated ambition to become a platform for all cell engineering including regenerative medicine. The company is preclinical; no sourced financing rounds are recorded.
Funding
All startupsPages like this
not linked directly; found by shared links- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyLiyfe
Shares Y Combinator and the tag yc.
- CompanyMednet (theMednet)
Shares Y Combinator and the tag yc.
- CompanyREPROSENT
Shares Y Combinator and the tag yc.
- CompanyAlixia
Shares Y Combinator and the tag yc.
- CompanyVelorum Therapeutics
Shares Y Combinator and the tag yc.
- CompanyDelee
Shares Y Combinator and the tag yc.
- CompanyResistanceBio (Viosera Therapeutics)
Shares Y Combinator and the tag yc.